Found to be superior to trivalent vaccine and non-inferior to monovalent vaccines
TUESDAY, Oct. 26 (HealthDay News) -- A novel bivalent oral poliovirus vaccine (bOPV) against poliovirus types 1 and 3 appears to be superior to trivalent OPV (tOPV) and non-inferior to monovalent type 1 OPV (mOPV1) and mOPV3, according to a study published online Oct. 26 in The Lancet.
In a randomized, double-blind, placebo-controlled trial, Roland W. Sutter, M.D., of the World Health Organization in Geneva, and colleagues evaluated the superiority of mOPV2, mOPV3, or bOPV over tOPV, and the non-inferiority of bOPV compared with mOPV1 and mOPV3. Nine hundred newborns were randomly assigned to receive either the mOPV, bOPV, or tOPV vaccines in two doses (birth and 30 days later), with 830 infants available for analysis.
The investigators found that bOPV induced a significantly higher immune response than tOPV and achieved higher seroconversion rates. The bOPV vaccine also showed similar efficacy to the respective mOPV vaccines. The mOPV, bOPV, and tOPV vaccines were well tolerated. Nineteen serious adverse events, including one death, occurred, but these were not attributable to the vaccine interventions.
"Our study confirmed that the bivalent vaccine leads to significantly more seroconversion than the trivalent vaccine. Additionally, the seroconversion rates and reverse cumulative distribution curves of neutralizing antibody titers were similar between the bivalent vaccine and the respective monovalent vaccines," the authors write.
The study was funded in part by Panacea Biotec. Two authors disclosed being employees of the company.
Abstract
Full Text (subscription or payment may be required)
Comment (subscription or payment may be required)